Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.

Weinstein MH, Partin AW, Veltri RW, Epstein JI.

Hum Pathol. 1996 Jul;27(7):683-7.

PMID:
8698312
[PubMed - indexed for MEDLINE]
2.

Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer.

Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D' Armiento M, De Placido S, Conti P, Di Lorenzo G.

Int J Immunopathol Pharmacol. 2007 Oct-Dec;20(4):765-70.

PMID:
18179749
[PubMed - indexed for MEDLINE]
3.

Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.

May M, Siegsmund M, Hammermann F, Loy V, Gunia S.

Scand J Urol Nephrol. 2007;41(5):375-81. Epub 2007 Jul 27.

PMID:
17853019
[PubMed - indexed for MEDLINE]
4.

Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.

Tamas EF, Epstein JI.

Am J Surg Pathol. 2006 Aug;30(8):980-5.

PMID:
16861969
[PubMed - indexed for MEDLINE]
5.
6.

Correlation of pathologic findings with progression after radical retropubic prostatectomy.

Epstein JI, Pizov G, Walsh PC.

Cancer. 1993 Jun 1;71(11):3582-93.

PMID:
7683970
[PubMed - indexed for MEDLINE]
7.

Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?

Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT.

J Urol. 1994 Nov;152(5 Pt 2):1843-9.

PMID:
7523732
[PubMed - indexed for MEDLINE]
8.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
9.

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J.

Urology. 2006 Jun;67(6):1247-52. Epub 2006 May 12.

PMID:
16697447
[PubMed - indexed for MEDLINE]
10.

The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy.

Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schröder FH.

Int J Cancer. 1995 Jul 28;62(3):252-8.

PMID:
7543077
[PubMed - indexed for MEDLINE]
11.

Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer.

Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT.

Hum Pathol. 1998 Aug;29(8):856-62.

PMID:
9712429
[PubMed - indexed for MEDLINE]
12.

Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume.

Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P.

Urology. 2000 Dec 20;56(6):1011-5.

PMID:
11113749
[PubMed - indexed for MEDLINE]
13.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
[PubMed - indexed for MEDLINE]
14.

Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.

Xing N, Qian J, Bostwick D, Bergstralh E, Young CY.

Prostate. 2001 Jun 15;48(1):7-15.

PMID:
11391682
[PubMed - indexed for MEDLINE]
15.

Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma.

Rioux-Leclercq NC, Chan DY, Epstein JI.

Urology. 2002 Oct;60(4):666-9.

PMID:
12385930
[PubMed - indexed for MEDLINE]
16.

Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.

Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.

J Urol. 2002 Jan;167(1):117-22. Erratum in: J Urol. 2004 Feb;171(2 Pt 1):811.

PMID:
11743287
[PubMed - indexed for MEDLINE]
17.

Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.

Zhou M, Hayasaka S, Taylor JM, Shah R, Proverbs-Singh T, Manley S, Rubin MA.

J Urol. 2001 Dec;166(6):2193-7.

PMID:
11696734
[PubMed - indexed for MEDLINE]
18.

Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.

Salomon L, Anastasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, Abbou CC, Olsson CA, Benson MC.

Urology. 2003 Aug;62(2):304-9.

PMID:
12893340
[PubMed - indexed for MEDLINE]
19.

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW.

J Urol. 1998 Aug;160(2):459-65.

PMID:
9679898
[PubMed - indexed for MEDLINE]
20.

Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.

Noguchi M, Stamey TA, McNeal JE, Yemoto CM.

J Urol. 2000 Nov;164(5):1596-600.

PMID:
11025712
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk